Results 131 to 140 of about 11,492 (188)
OMALIZUMAB FOR CHILDREN WITH BRONCHIAL ASTHMA: INDICATIONS TO APPLICATION
Педиатрическая фармакология, 2007 Antibodies to IgE are a totally new class of medications currently used to enhance the supervision over severe persistent atopic bronchial asthma. Omalizumab is the most well studied, first and only medication of this group, which is recommended for the ...
T.V. Kulichenko
doaj
The pediatric asthma yardstick: Practical recommendations for a sustained step-up in asthma therapy for children with inadequately controlled asthma [PDF]
, 2018 Bacharier, Leonard B +8 more
core +2 more sources
Coumarins and Their Derivatives in Animal Models of Asthma: A Systematic Review
Basic &Clinical Pharmacology &Toxicology, Volume 138, Issue 3, March 2026.Mast cells drive early allergic asthma by releasing histamine, interleukins and prostaglandins, causing airway hyperresponsiveness, mucus overproduction and inflammation. These events sustain symptoms and promote structural remodelling, contributing to the progression of the disease.
Iêda Maria dos Santos +3 more
wiley +1 more source
Clinical &Experimental Allergy, Volume 56, Issue 3, Page 212-226, March 2026.Real‐world patients with severe eosinophilic asthma treated with benralizumab showed early and sustained improvements in symptoms. Clinically meaningful improvements began as early as one week after benralizumab initiation, regardless of previous biologic use, and further improved over the following year.
Erika Penz +12 more
wiley +1 more source
Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N‐ERD Patients
Clinical &Experimental Allergy, Volume 56, Issue 3, Page 227-242, March 2026.Dupilumab therapy reduced elevated type 2 cytokine responses post‐ASA provocation in N‐ERD patients, independent of ASA tolerance, and revealed novel mechanistic insights by modulating acute type 2 immunity. Transcriptomic analysis showed concurrent downregulation of lipid and peroxisome pathways during ASA challenge in N‐ERD patients after 24 weeks of
Julia Eckl‐Dorna +10 more
wiley +1 more source
Clinical and Translational Allergy, Volume 16, Issue 3, March 2026.
Si Yuan Leow +10 more
wiley +1 more source
Clinical Otolaryngology, Volume 51, Issue 2, Page 275-284, March 2026.ABSTRACT Objective To identify sociodemographic and clinical predictors of symptom severity and quality of life (QoL) impairment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), diagnosed according to the latest EPOS 2020 criteria. Study Design Cross‐sectional analytical study.
Javier Modesto García‐Fernández +5 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 3, March 2026.ABSTRACT QX008N, a humanized IgG1 monoclonal antibody against thymic stromal lymphopoietin (TSLP) with Fc engineering to extend half‐life, was developed with the aim of exploring whether its extended half‐life and cost‐effective production could potentially address unmet needs in severe asthma therapy, such as the need for less frequent dosing and ...
Zhen‐Wei Shen +7 more
wiley +1 more source
Care pathways for the selection of a biologic in severe asthma [PDF]
, 2017 Bousquet, Jean +12 more
core +2 more sources